Pratz, K W <br/><br/>
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.  [electronic resource] 

 -  Leukemia  Aug 2010 
 - 1437-44 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2010.132  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacokinetics<br/>Benzenesulfonates--pharmacokinetics<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--blood<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Pyridines--pharmacokinetics<br/>Recurrence<br/>Sorafenib<br/>fms-Like Tyrosine Kinase 3--antagonists & inhibitors